A new study shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone.
MEDIZIN.NEWZS.de – Quantum Related Diseases Research Group (QRDRG)
Forschungsgruppe Quanteneffekte bei Krankheiten (qrdrg.xonl.de)